Cargando…
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients’ prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. H...
Autores principales: | Russano, Marco, La Cava, Giulia, Cortellini, Alessio, Citarella, Fabrizio, Galletti, Alessandro, Di Fazio, Giuseppina Rita, Santo, Valentina, Brunetti, Leonardo, Vendittelli, Alessia, Fioroni, Iacopo, Pantano, Francesco, Tonini, Giuseppe, Vincenzi, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955173/ https://www.ncbi.nlm.nih.gov/pubmed/36826142 http://dx.doi.org/10.3390/curroncol30020181 |
Ejemplares similares
-
Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020) -
Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020) -
Steroid-refractory immune related hepatitis may hide viral re-activation
por: Citarella, Fabrizio, et al.
Publicado: (2020) -
Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019) -
Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)